How Independent Pharmacies Are Valued
Independent pharmacy valuation has become increasingly challenging as PBM (Pharmacy Benefit Manager) reimbursement rates continue to compress retail margins. The traditional retail pharmacy selling prescriptions at a markup faces structural decline, but specialty pharmacy, compounding, 340B programs, and clinical services create pockets of premium value within the sector.
Traditional Retail Pharmacy
A standard independent retail pharmacy sells for an SDE-multiple range. A pharmacy doing $3M in revenue with $250K SDE would sell for $375K to $875K. The wide range reflects the enormous variance in prescription volume, front-end sales, PBM contract terms, and 340B eligibility. Pharmacies with strong script volume (200+/day) and favorable PBM contracts trade at the higher end.
An alternative valuation method uses per-prescription multiples of a per-script range (monthly prescription count x multiple). A pharmacy filling 5,000 Rx/month would be valued at $15K-$40K per month of scripts, or $180K-$480K. This method is commonly used as a cross-check against SDE-based valuations.
Specialty Pharmacy
Specialty pharmacies, those dispensing high-cost medications for complex conditions (oncology, rheumatology, HIV, hepatitis), command platform-tier earnings multiples. The premium reflects higher per-prescription revenue ($2,000-$10,000+ per Rx vs. $50-$100 for retail), stickier patient relationships, and limited competition due to accreditation requirements. Specialty pharmacy has attracted significant PE interest.
340B Pharmacies
Pharmacies participating in the 340B Drug Pricing Program, which allows eligible health systems to purchase outpatient drugs at significantly reduced prices, generate outsized margins on qualifying prescriptions. A pharmacy with a strong 340B program can achieve 40-60% gross margins on 340B scripts versus 18-22% on commercial scripts. This premium is reflected in valuations, though buyers also assess 340B regulatory risk as the program faces ongoing Congressional scrutiny.
Key Value Drivers
Prescription volume and trend is the baseline metric. Growing script counts signal a healthy pharmacy. Declining counts, especially if driven by PBM network exclusions, are a major red flag. Buyers analyze script count trends over 36 months and segment by payor to identify vulnerability.
PBM contract terms directly determine margin sustainability. Pharmacies locked into unfavorable MAC (Maximum Allowable Cost) lists or facing DIR (Direct and Indirect Remuneration) fee clawbacks have structurally lower margins. Buyers model reimbursement at the NDC (National Drug Code) level to assess true prescription profitability.
Front-end and clinical services revenue diversifies the business beyond prescription dispensing. Pharmacies generating meaningful revenue from immunizations, medication therapy management (MTM), clinical testing, compounding, or durable medical equipment are less dependent on razor-thin dispensing margins.
Location and competitive dynamics matter. Pharmacies in underserved rural areas or medical deserts have more pricing power and less competition than those competing with CVS, Walgreens, and Walmart pharmacies on every corner. Proximity to physician offices and hospitals drives referral volume.